An injectable treatment for HIV could be more effective than a daily oral therapy, data suggests. 

Results from the LATITUDE study of Cabenuva (cabotegravir + rilpivirine), a long-acting injectable developed by HIV specialist ViiV Healthcare, show the switch to the injectable reduced risk of virological failure by nearly half compared to daily oral therapy. 

The 48-week data, published in the New England Journal of Medicine, followed a February 2024 recommendation from an independent Data and Safety Monitoring Board to halt randomisation in the study and invite all eligible study participants to take long-acting injectable Cabenuva based on interim efficacy data. 

Once enrolled, participants received adherence support including conditional economic incentives to achieve viral suppression while taking guideline-recommended daily oral antiretroviral treatment (ART). Researchers randomised 306 participants who were able to achieve viral suppression to either receive the long-acting injectable every four weeks or continue taking daily oral ART. 

“The LATITUDE study adds to a robust body of evidence supporting the role of long-acting injectable cabotegravir + rilpivirine as a valuable treatment option for people living with HIV,” said Kimberly Smith, Head of Research & Development at ViiV Healthcare. 

“This is the first randomised study confirming this regimen is superior to daily oral therapy in this population. As such, these findings have the potential to validate a long-acting approach for this additional group of patients and could make a significant difference to people living with HIV and our goal of ending the epidemic.”